Plain-English translation of NCT05210907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called , which is made by taking your own immune cells, modifying them in the laboratory to fight leukemia cells, and then putting them back into your body. The treatment is designed for children and teenagers with acute lymphoblastic leukemia that has come back or hasn't responded to standard chemotherapy. Researchers want to see if this medication is safe and how well it works for patients who have run out of other options.
Children and teenagers with leukemia that keeps coming back or doesn't respond to regular chemotherapy have very few treatment choices left and a poor outlook. This new treatment was developed to offer hope to patients in this difficult situation by using the body's own immune system in a new way.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the trial, you will receive the medication as an intravenous infusion (through an IV in your vein). The trial will carefully monitor your safety and how your body responds to the treatment. You will need to visit the hospital for the infusion and for follow-up appointments where doctors will check your blood counts, overall health, and how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea